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ABSTRACT Critically ill patients frequently have substantially altered pharmacoki-
netics compared to non-critically ill patients. We investigated the impact of pharma-
cokinetic alterations on bacterial killing and resistance for commonly used mero-
penem dosing regimens. A Pseudomonas aeruginosa isolate (MICmeropenem 0.25 mg/
liter) was studied in the hollow-ﬁber infection model (inoculum 107.5 CFU/ml; 10
days). Pharmacokinetic proﬁles representing critically ill patients with augmented re-
nal clearance (ARC), normal, or impaired renal function (creatinine clearances of 285,
120, or 10 ml/min, respectively) were generated for three meropenem regimens (2,
1, and 0.5 g administered as 8-hourly 30-min infusions), plus 1 g given 12 hourly
with impaired renal function. The time course of total and less-susceptible popula-
tions and MICs were determined. Mechanism-based modeling (MBM) was performed
using S-ADAPT. All dosing regimens across all renal functions produced similar initial
bacterial killing (2.5 log10). For all regimens subjected to ARC, regrowth occurred
after 7 h. For normal and impaired renal function, bacterial killing continued until 23
to 47 h; regrowth then occurred with 0.5- and 1-g regimens with normal renal func-
tion (fT5MIC  56 and 69%, fCmin/MIC  2); the emergence of less-susceptible
populations (32-fold increases in MIC) accompanied all regrowth. Bacterial counts
remained suppressed across 10 days with normal (2-g 8-hourly regimen) and im-
paired (all regimens) renal function (fT5MIC  82%, fCmin/MIC  2). The MBM suc-
cessfully described bacterial killing and regrowth for all renal functions and regimens
simultaneously. Optimized dosing regimens, including extended infusions and/or
combinations, supported by MBM and Monte Carlo simulations, should be evaluated
in the context of ARC to maximize bacterial killing and suppress resistance emer-
gence.
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Effective antibiotic therapy is a crucial determinant of survival for patients withserious infections in an intensive care unit (ICU) (1, 2). Serious infections caused by
Pseudomonas aeruginosa are increasing in prevalence in ICUs and present a substantial
problem (3–5). Mortality rates exceed 50% for speciﬁc patient groups such as those
with septic shock (6), with early administration of effective antibiotic therapy substan-
tially improving survival (1, 7). Meropenem is a common treatment for P. aeruginosa
infections (5, 8). It is well recognized that for -lactam antibiotics such as meropenem
the fraction of a dosing interval where unbound concentrations exceed 1 MIC of the
infecting pathogen (fTMIC) should be optimized to achieve near-maximal bacterial
killing (9, 10). Furthermore, it has become evident that higher exposures, e.g., unbound
concentrations remaining above 4 or 5 MIC throughout the dosing interval or a
minimum unbound concentration (fCmin) of 4 MIC is required for the suppression
of the emergence of resistance (11–14). The emergence of antibiotic resistance in
patients occurs in 10% of antibiotic courses (15), with suboptimal dosing an impor-
tant contributor (16).
Attainment of pharmacokinetic/pharmacodynamic (PK/PD) targets is challenging in
critically ill patients who can have signiﬁcantly altered antibiotic pharmacokinetics
compared to non-critically ill patients (17, 18). In particular, patients with augmented
renal clearance (ARC) have been demonstrated to exhibit substantially increased
meropenem clearances and thereby decreased meropenem exposures (17, 19–21). This
results in a signiﬁcant risk of subtherapeutic antibiotic concentrations. However, the
impact of a wide range of renal functions, including ARC, on bacterial killing and
resistance emergence has not been quantiﬁed for meropenem. At present, clinicians
still rely predominantly on the product information when selecting dosing regimens
instead of adjusting the doses for patients with ARC (22, 23).
The hollow-ﬁber infection model (HFIM) can simulate the time course of antibiotic
concentrations with a speciﬁc elimination half-life at high inocula over long durations,
both of which are typically not possible with in vivo models. Results from the HFIM are
also well correlated with clinical endpoints for bacterial killing and time course of
emergence of resistance (24). This study used the HFIM to characterize the effect of
different meropenem exposures, administered as standard short-term infusions, likely
to occur in critically ill patients on the bacterial killing and emergence of resistance for
P. aeruginosa. Speciﬁcally, we generated unbound concentration-time proﬁles consis-
tent with those observed in patients with augmented renal clearance (ARC), and those
with normal and impaired renal function following intravenous (i.v.) administration of
four commonly used dosing regimens. We additionally developed a mechanism-based
mathematical model (MBM) to quantitatively characterize the relationships between
meropenem concentrations, bacterial killing, and regrowth over time for a wide range
of studied renal functions and dosing regimens.
(Parts of this study were presented at the American Society for Microbiology
Microbe and Interscience Conference on Antimicrobial Agents and Chemotherapy
Congress, Boston, MA, 16 to 20 June 2016, and the Australasian Society of Clinical and
Experimental Pharmacologists and Toxicologists and Molecular Pharmacology of GPCRs
meeting, Melbourne, Australia, 27 to 30 November 2016.)
RESULTS
Typical examples of observed, targeted, and ﬁtted concentration-time proﬁles are
shown in Fig. S1 in the supplemental material. Measured meropenem concentrations
adequately matched the target proﬁles produced in the in silico design simulations (Fig.
1; see also Fig. S1). The ﬁtted meropenem concentration-time proﬁles were used in the
MBM. Changes in total and less-susceptible bacterial populations are shown in Fig. 2
and 3. Changes in mutation frequencies and MICs are presented in Tables 1 and 2. The
log10 mutation frequency (log10MF) before treatment (0 h) was 5.56 to 6.88 on
agar containing 5 and 10 the meropenem MIC (Table 1). Very few colonies grew on
antibiotic-containing agar prior to treatment (Fig. 3).
At all levels of renal function (CLCR) the three growth controls were virtually
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superimposable, with less-susceptible populations (i.e., those growing in the presence
of meropenem at 5 and 10 MIC) plateauing at about 3 to 4 log10 CFU/ml by about
48 to 72 h (Fig. 3). The log10MFs and MICs were also relatively stable, with MICs
generally within one (occasionally two) 2-fold dilutions of the baseline when colonies
were detected. At each CLCR, bacterial killing over the ﬁrst 7 h was similar (about 1.5 to
2.5 log10 killing; Fig. 2) with all meropenem-containing regimens. However, for all regi-
mens subject to ARC, little or no further bacterial killing occurred with regrowth to within
1.5-log10 of control values by 48 h (0.5- and 1-g regimens) and 96 h (2-g regimen). In each
case less-susceptible populations emerged rapidly growing to within2 log of the total
population, with MICs at each concentration (5 and 10MIC) increasing to 16 mg/liter
(0.5-g regimen) and 32 mg/liter (1- and 2-g regimens) by 191 h. For normal and
impaired renal function, all regimens demonstrated essentially identical bacterial killing
up to 23 h (1-log difference between all regimens). At normal renal function, rapid
regrowth with near-complete replacement of susceptible by less-susceptible bacteria
(Fig. 3) and a concomitant increase in mutation frequency and MIC (Tables 1 and 2)
occurred with the 0.5-g regimen after 23 h. With normal renal function, similar regrowth
and resistance emergence occurred with the 1-g regimen, although regrowth was
delayed until 48 h, whereas killing continued and/or regrowth remained suppressed
across 10 days with the 2-g regimen. With impaired renal function all regimens
(including 1 g 12-hourly) suppressed regrowth across 10 days. In each case where
regrowth was suppressed, no viable bacteria were detected on at least one occasion
from 143 h onward; viable bacteria (maximum of 1.54 log10 CFU/ml; no less-susceptible
bacteria) were detected in only three of the ﬁve regimens at 239 h.
The developed MBM was able to successfully describe simultaneously the mero-
FIG 1 Observed versus individual ﬁtted (top) and population ﬁtted (bottom) viable counts for four meropenem
dosing regimens and three different renal functions (circles, CLCR 10 ml/min; triangles, CLCR 120 ml/min, plus
signs, CLCR 285 ml/min). Observations below the limit of counting are not shown on the graphs.
Effect of Meropenem Clearance on Antibacterial Effects Antimicrobial Agents and Chemotherapy
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penem concentrations and viable bacterial counts for all renal functions and dosing
regimens that were evaluated in the HFIM (Fig. 1 and 4; see also Fig. S1 in the
supplemental material). Three subpopulations were required to ﬁt the observed bac-
terial counts, with the intermediate and resistant subpopulations growing more slowly
than the susceptible subpopulation (k121; Table 3). A model incorporating inhibition
of successful replication of all three bacterial subpopulations by meropenem best
described the antibacterial effect. No additional functions or model complexities were
necessary. The meropenem concentration required for half-maximal inhibition of suc-
cessful bacterial replication of the intermediate (IC50 Rep,I) and resistant (IC50Rep,R)
populations was 5- and 10-fold higher than for the susceptible population (IC50 Rep,S;
Table 3). In this model, the resistant bacterial population (CFUR) was responsible for
driving the bacterial regrowth, which was observed with all dosing regimens subjected
to ARC and with the 0.5- and 1-g 8-hourly dosing regimens at normal renal functions.
DISCUSSION
This study demonstrated the impact of altered meropenem pharmacokinetics as
observed in critically ill patients on the likely antibacterial effects. Although the level of
bacterial killing with all regimens at all renal functions was initially similar despite an
36-fold range in average steady-state unbound concentrations, subsequent differ-
ences with repeated dosing were substantial. In the presence of ARC, all meropenem
dosing regimens quickly failed with a rapid and substantial emergence of less-
susceptible populations 1,000-fold greater than that observed with control regimens,
with accompanying increases in MICs and mutation frequencies. Such rapid regrowth
of less-susceptible bacteria after minimal initial killing even with the 2-g dose is very
concerning, given that ARC (deﬁned as a CLCR  130 ml/min) can occur in up to 65%
of critically ill patients, many with a CLCR of 200 to 300 ml/min (25). The failure of these
traditional dosing regimens is particularly worrying given the low meropenem MIC of
the studied clinical isolate.
At normal renal function, rapid regrowth and extensive emergence of less-
susceptible populations was observed with the 0.5- and 1-g 8-hourly regimens,
although this occurred about 24 to 48 h later than with ARC and followed a greater
initial killing of about 3 to 4 log10 CFU/ml. Drusano et al. (26) demonstrated for P.
FIG 2 Time-kill curves with three different levels of renal function (CLCR of 285, 120 and 10 ml/min, corresponding to meropenem
clearances of 34.0, 16.3 and 4.1 L/h, respectively) using three clinically relevant dosing regimens of meropenem (2g, 1g and 0.5g IV
given 8-hourly; administered as a 0.5 h infusion). For patients with renal impairment (CLCR of 10 ml/min), a 1g IV regimen given
12-hourly was also simulated. For growth controls, ﬂow rates for the respective renal functions were used. Samples with no colonies
present on agar plates were plotted at the limit of counting (1.0 log10 CFU/ml).
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FIG 3 Effect of each level of renal function (CLCR of 285, 120 and 10 ml/min) with each dosing regimen on the total bacterial population and
less-susceptible populations (i.e., able to grow in the presence of 5 or 10 the meropenem MIC). For growth controls, ﬂow rates for the respective
renal functions were used.
Effect of Meropenem Clearance on Antibacterial Effects Antimicrobial Agents and Chemotherapy
May 2017 Volume 61 Issue 5 e02642-16 aac.asm.org 5
 o
n
 M
ay 10, 2018 by University of Queensland Library
http://aac.asm
.org/
D
ow
nloaded from
 
aeruginosa and Staphylococcus aureus in a murine thigh infection model that, while
granulocytes contribute to the elimination of bacteria up to a certain level, this effect
is saturable. In the HFIM simulating normal renal function (but without an immune
system) the 1-g 8-hourly regimen did not reduce bacteria to below 3.5 log10 CFU/ml,
TABLE 1 Log10 mutation frequencies at 1.25 and 2.5 mg/liter (5 and 10 the baseline MIC) at various time points for each dosing
regimen and CLCR simulated in the HFIMa
Dose
(mg/liter) Time (h)
CLCR, 285 ml/min (t1/2, 0.6 h) CLCR, 120 ml/min (t1/2, 1.1 h) CLCR, 10 ml/min (t1/2, 4 h)
Control 2 g, 8 h 1 g, 8 h 0.5 g, 8 h Control 2 g, 8 h 1 g, 8 h 0.5 g, 8 h Control 2 g, 8 h 1 g, 8 h 0.5 g, 8 h 1 g, 12 h
1.25 (5 MIC) 0 5.89 6.66b 6.66 6.66 6.88 6.88 6.88 6.88 5.56 5.56 6.76 5.77 5.77
23 6.31 5.34 6.33 5.51 7.36 2.7 3.47 2.80 6.82 2.62 2.91 3.05 3.03
47 6.39 3.54 2.55 3.84 7.05 1.85 2.89 2.81 6.43 1.64 1.89 1.66 1.45
71 6.37 3.20 2.24 3.06 6.35 2.96 2.25 0.38 5.81 1.08 0.48 1.41 0.78
95 6.38 1.45 0.56 6.20 0.30 0.30 0.30 0.60
119 6.74 3.52 2.86 3.83 7.14 1.64 1.97 0.44 5.67 0.49 0.25 2.13 1.15
143 5.61 2.48 0.34 5.76 NC  0.6 1.38 0.84
167 6.94 1.06 2.96 2.99 7.24 2.12 2.26 0.41 6.16 0.68 1.55 1.00 NC
191 6.98 0.08 2.80 2.90 7.66 1.76 1.21 0.41 5.97 0.54 0.28 NC NC
215 6.02 2.25 0.31 5.78 NC NC 2.13 0.60
239 6.45 1.70 1.82 1.44 7.30 NCc 1.68 0.59 5.43 0.30 0.30 0.70 NC
2.5 (10 MIC) 0 6.59  6.66 6.66 6.66 6.88 6.88 6.88 6.88 6.34 6.34 6.76 6.25 6.25
23 7.64  5.34 6.33 4.78 7.33 2.7 3.47 3.4 7.27 2.62 2.91 3.05 3.03
47 7.32 5.17 3.76 4.17 9.3 1.85 3.19 2.89 7.00 1.64 1.89 1.66 1.45
71 7.68 3.63 2.97 4.15 8.05 2.96 1.68 0.34 6.10 1.08 0.34 1.41 0.78
95 7.39 2.85 0.05 6.20 0.00 0.30 0.30 0.60
119 7.44 4.51 3.35 4.67 7.40 1.57 2.11 0.41 6.08 0.58 0.32 2.13 1.15
143 7.14 2.48 0.67 5.88 NC 0.6 1.38 1.77
167 8.06 3.09 2.99 3.34 7.49 2.33 2.52 0.505 6.48 1.15 1.69 1.00 NC
191 7.46 2.94 2.89 3.20 7.36 1.76 2.28 0.566 6.12 0.72 0.48 NC NC
215 6.55 2.69 0.405 6.48 NC NC 2.13 0.60
239 6.59 2.24 2.63 2.31 8.72 NC 1.90 0.495 5.41 0.34 0.54 0.85 NC
aWhen no colonies were present on antibiotic-containing plates, mutation frequencies reported represent an upper limit based on the total viable count. Dosing
regimens in the column subheadings are expressed as “amount, dosing interval.”
bThe log10 baseline mutation frequency determined at a higher bacterial density in a separate experiment was 8.05 at 5 MIC.
cNC, no colonies were detected on both drug-free and drug-containing agar plates.
TABLE 2MIC values from colonies obtained from drug-containing (5 and 10 the baseline MIC, equivalent to meropenem at 1.25 and
2.5 mg/liter) agar plates at various time points for each dosing regimen and CLCR simulated in the HFIM
Meropenem regimen
(amt, dosing interval) Time (h)
MICa
CLCR, 285 ml/min CLCR, 120 ml/min CLCR, 10 ml/min
5 MIC
plates
10 MIC
plates
5 MIC
plates
10 MIC
plates
5 MIC
plates
10 MIC
plates
Control 0 2/8 NCc 2/8 2/4 2/4 NC
47 2/8 2/4 8/8 4/4 4/8 4/8
191 2/4 2/4 2/4 4/4 4/8 4/8
2 g, 8 h 0 NC NC NC NC NC NC
47 8/8 8/16 NC NC NC NC
191 16/32 16/32 NC NC 8/16 64/64
1 g, 8 h 0 NC NC NC NC NC NC
47 16/32 16/32 2/4 NC NC NC
191 16/32 16/32 4/8 8/16 16/16 32/32
0.5 g, 8 h 0 NC NC NC NC 2/4 NC
47 8/8 8/8 2/4 32/32 NC NC
191 8/16 8/16 8/8 32/32 NC NC
1 g, 12 hb 0 NC NC
47 NC NC
191 NC NC
aSusceptibility and resistance to meropenem are deﬁned as MIC 2 mg/liter and MIC 8 mg/liter, respectively (57). MICs were determined according to the CLSI agar
dilution method (56), and readings taken at both 24 and 48 h are reported (24 h/48 h).
bOnly performed with a CLCR of 10 ml/min.
cNC, no colonies detected.
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with replacement of susceptible by less-susceptible bacteria occurring. Therefore,
treatment failure with the 1-g 8-hourly regimen in patients with normal renal function
is a distinct (and concerning) possibility even considering the potential added effect of
the immune system. Replacement of susceptible by less-susceptible bacteria also has
potential long-term implications for both individual patients and infection control. In
contrast, the 2-g dosing regimen at normal renal function and all regimens (including the
1-g 12-hourly regimen) evaluated in impaired renal function resulted in complete or
near-complete bacterial killing. We have previously reported similar results for piperacillin-
tazobactam against P. aeruginosa (14), although the emergence of resistant subpopulations
in the presence of ARC was greater for meropenem.
Results from studies examining -lactams, including meropenem, undertaken in the
HFIM correlate well with those from neutropenic mouse models and predicted emer-
gence of resistance in patients (27–30). However, of the few studies examining mero-
penem against a variety of pathogens in the HFIM, none have included a half-life
representative of ARC (31–33). In addition, very few have examined the emergence of
resistance to meropenem, which is known to occur primarily via downregulation of the
gene for the outer membrane porin OprD (which allows entry of carbapenems into the
cell) and overexpression of efﬂux pumps MexAB-OprM, MexXY-OprM, and MexCD-OprJ
(34–40). Louie et al. (13) used a P. aeruginosa wild-type strain (MIC 0.5 mg/liter) and its
MexAB pump-overexpressed mutant (MIC  2 mg/liter) to evaluate meropenem (1-, 2-,
and 3 g, 8-hourly regimen via a 1-h [wild-type] or 4-h [pump-overexpressed mutant]
infusion; t1/2  1 h) over 14 days. All regimens for the wild-type had a fTMIC of 100%.
For both isolates, monotherapy with 1- and 2-g regimens produced approximately 2-
and 4-log10 killing over the ﬁrst 48 h, respectively, followed by rapid regrowth due to
ampliﬁcation of less-susceptible subpopulations (able to grow at 5 MIC). In contrast,
the 3-g regimen suppressed regrowth (wild-type) or eradicated the bacteria (mutant).
FIG 4 Model ﬁts to the observed bacterial count proﬁles over time, grouped by simulated CLCR. Samples
with no colonies present on agar plates were plotted at the limit of counting (1.0 log10 CFU/ml).
Effect of Meropenem Clearance on Antibacterial Effects Antimicrobial Agents and Chemotherapy
May 2017 Volume 61 Issue 5 e02642-16 aac.asm.org 7
 o
n
 M
ay 10, 2018 by University of Queensland Library
http://aac.asm
.org/
D
ow
nloaded from
 
Tam et al. (11) investigated varying the meropenem half-life (to alter Cmin) while
keeping the Cmax at 64 mg/liter using a P. aeruginosa reference strain and its stably
depressed AmpC -lactamase-producing isogenic mutant (MIC  1 mg/liter for both).
Bolus doses were administered 8 hourly for 5 days with half-lives ranging from about
1 to 3 h (i.e., not representative of patients with ARC); fTMIC was 75% (one regimen)
and 100% (three regimens). For both strains at the shortest half-lives (approximately 1
and 1.6 h), regrowth and ampliﬁcation of less-susceptible subpopulations (growing at
3 MIC) followed moderate initial killing. At the longer half-lives (about 2.4 and 3 h),
regrowth was suppressed without ampliﬁcation of less-susceptible subpopulations.
These results broadly match those of the present study for normal renal function and
renal impairment, although in the present study with a more susceptible isolate, the 2-g
8-hourly regimen with normal renal function suppressed regrowth. We have also
shown the rapid failure and emergence of resistance of commonly used regimens even
at the highest approved daily dose in the presence of ARC.
The fTMIC required for optimal bactericidal activity of carbapenems, derived from
in vitro studies and animal in vivo studies, is generally reported to be 40% (10, 41).
However, it is also important to consider the emergence of resistance. In our study, the
fTMIC of all failed regimens exceeded 40% (Table 4). However, as also observed in the
studies described above (11, 13), treatment failure with rapid resistance emergence
nonetheless occurred even in some situations where fTMIC was at or close to 100%.
Such in vitro ﬁndings plus data from recent retrospective clinical studies supporting a
longer fTMIC in critically ill patients (42–45) challenge the traditional PK/PD targets.
With maximal bactericidal activity of the -lactams occurring at 4 to 5 MIC (46, 47)
and regrowth often observed as soon as concentrations fall below the MIC (48–50),
other targets, e.g., 100% fT4–5MIC (14, 51, 52) and fCmin/MIC, have been investigated.
TABLE 3 Population parameter estimates for meropenem against P. aeruginosa 1280
Parameter Term U
Estimate
(SE)d
Growth parameters
Log10 initial inoculum LogCFU0 Log10 CFU/ml 6.97 (1.5)
Mean generation time
Susceptible population k12,S1 min 49.3 (9.5)
Intermediate population k12,I1 min 683 (19)
Resistant population k12,R1 min 78.5 (10.4)
Replication rate constant k21 h1 50 (ﬁxed)a
Log10 (maximum population size) LogCFUmax Log10 CFU/ml 9.98 (0.9)
Log10 (mutation frequencies)
Intermediate population LogMFI 3.66 (5.2)
Resistant population LogMFR 6.28 (6.9)
Inhibition of probability of successful replication
by meropenem
Maximum inhibition
Susceptible population Imax Rep,S 1.0 (ﬁxed)b
Intermediate population Imax Rep,I 0.673 (56.3)
Resistant population Imax Rep,R 0.956 (25.0)
Concn causing 50% of inhibition
Susceptible population IC50 Rep,S mg/liter 0.648 (39.8)
Intermediate population IC50 Rep,I mg/liter 2.96 (45.3)
Resistant population IC50 Rep,R mg/liter 6.09 (23.3)
Hill coefﬁcient
Susceptible population Hill,S 1.0 (ﬁxed)c
Intermediate population Hill,I 7.14 (23.9)
Resistant population Hill,R 2.19 (62.3)
SD of additive residual error on log10 scale SDCFU Log10 CFU/ml 0.493
aBacterial replication was assumed to be fast, as previously described (14, 54, 67).
bThe Imax Rep,S was estimated at 0.999 and therefore was eventually ﬁxed to 1.0.
cHill,S was estimated at 1.03 and therefore was eventually ﬁxed to 1.0.
dStandard errors (in parentheses) are expressed as percentages.
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Both Tam and Louie et al. examined the fCmin/MIC value in relation to the suppression
of the emergence of resistance (11–13). Regimens where the fCmin/MIC was2 failed
with rapid regrowth and emergence of resistance, whereas a value of 3 (or, for Tam
et al., of 6, the next lowest fCmin/MIC examined) prevented regrowth and suppressed
resistance. Tam et al. (12) subsequently utilized mathematical modeling to determine
a value of 4 was required. A retrospective clinical study utilizing population pharma-
cokinetic modeling to estimate meropenem pharmacokinetic parameters for lower
respiratory tract infections found that an fCmin/MIC  5 was the most signiﬁcant
predictor of successful clinical and microbiological response, although P. aeruginosa
was only one of a range of pathogens included and resistance emergence was not
examined (43). In our study, all regimens with a fCmin/MIC  1 failed, with resistance
emerging, whereas those with a fCmin/MIC  2 suppressed regrowth. Also, both
regimens that failed despite a fTMIC at or close to 100% had an fT5MIC well below
100% (0.5- and 1-g regimens with normal renal function, i.e., fT5MIC values of 56 and
69%, respectively; Table 4). All regimens achieving 100% fT5MIC were successful, as
was the 2-g regimen at normal renal function where concentrations exceeded 5 MIC
for 82% of the dosing interval. Such ﬁndings are consistent with our earlier study
utilizing piperacillin-tazobactam against P. aeruginosa, where all regimens achieving
100% fT5MIC suppressed regrowth and the emergence of resistance. Clearly, such
targets cannot be achieved in the presence of ARC with current commonly used
short-term infusion regimens, even at the highest approved daily dose.
The antibacterial effect of meropenem was best described by a model including the
inhibition of successful replication, as described for studies with other -lactams where
bacterial killing was found to be less rapid than growth (14, 53). The meropenem
proﬁles from all regimens with ARC and the 1- and 0.5-g 8-hourly regimens at normal
renal function did not suppress regrowth of the resistant population in the model. This
is in agreement with a high proportion of bacteria being able to grow on meropenem-
containing agar (Fig. 3, Table 1). Although some bacterial counts at 119 and 167 h were
slightly underpredicted by the model, this was attributed to experimental variability at
relatively low bacterial counts. Since the model well described the bacterial counts and
pharmacokinetic proﬁles over a large range of renal functions and meropenem con-
centrations, it may be useful for predicting the antibacterial effects of meropenem for
other than the studied renal functions and ultimately to develop optimized dosing
regimens (54, 55). Although the simulation of plasma instead of tissue concentrations
TABLE 4Meropenem dosing regimens and pharmacokinetic parameters for three different simulated levels of renal function used in the
HFIM against P. aeruginosa 1280a
Meropenem regimen
(amt, dosing interval)b
CLCRc
(ml/min)
CLmeropenem
(liters/h)
t1/2d
(h)
fCmax
(mg/liter)
fCmin
(mg/liter) fCmin/MIC
fCss,avg
(mg/liter) %fT>MIC %fT>5MIC
fAUC24
(mg·h/liter) Outcomee
2 g, 8 h 285 34.0 0.6 51.3 0.01 0.04 7.1 62 45 170.7 RR
1 g, 8 h 285 34.0 0.6 25.7 0.00 0.00 3.6 54 38 85.3 RR
0.5 g, 8 h 285 34.0 0.6 12.8 0.00 0.00 1.8 47 30 42.7 RR
2 g, 8 h 120 16.3 1.1 70.1 0.50 2.0 15.5 100 82 372.4 SR
1 g, 8 h 120 16.3 1.1 35.0 0.25 1.0 7.8 100 69 186.2 RR
0.5 g, 8 h 120 16.3 1.1 17.5 0.12 0.48 3.9 87 56 93.1 RR
2 g, 8 10 4.1 4.0 114.5 31.5 126.0 64.9 100 100 1556.9 SR
1 g, 8 h 10 4.1 4.0 57.2 15.7 62.8 32.4 100 100 778.5 SR
0.5 g, 8 h 10 4.1 4.0 28.6 7.9 31.6 16.2 100 100 389.2 SR
1 g, 12 h 10 4.1 4.0 49.1 6.8 27.2 21.6 100 100 519.3 SR
aFor P. aeruginosa 1280, the meropenem MIC is 0.25 mg/liter. All values presented are concentrations simulated at steady state. Abbreviations: t1/2, half-life; fCmax,
unbound maximal concentration at steady state; fCmin, unbound minimal concentration; fCss,avg, unbound average concentration at steady state; %fTMIC, the
percentage of time that unbound concentrations exceeded the MIC; AUC24, the area under the unbound piperacillin concentration-versus-time curves over 24 h.
bThe infusion time for all regimens was 0.5 h.
cA creatinine clearance (CLCR) of 285 ml/min represents patients with augmented renal clearance, a CLCR of 120 ml/min represents patients with normal renal
clearance, and a CLCR of 10 ml/min represents patients with renal impairment.
dSamples for viable counting were collected at 0, 1.5, 5, 7, 13, 23, 29, 31, 47, 53, 71, 95, 119, 143, 167, 191, 215, and 239 h. Samples for pharmacokinetic
determinations were collected at 0.66, 1, 2, 3.5, 5, 7, 8.66, 13, 23, 24.66, 47, 48.66, 49, 50, 51.5, 53, 55, 71, 72.66, 95, 119, 143, and 167 h for the CLCR of 285 ml/min.
For the CLCR at 120 and 10 ml/min, samples were collected as for the 285-ml/min CLCR, as well as at 29 and 31 h. For growth controls, the ﬂow rates for the
respective renal functions were maintained.
eRR, regrowth, with resistance; SR, suppression of regrowth.
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in the HFIM is a potential limitation, our study best reﬂects the clinical scenario of
bloodstream infections. An effect of the immune system, which was absent in the HFIM,
may in the future be incorporated into our MBM using data derived from animal studies
(26).
In conclusion, this study is the ﬁrst to examine the effects of altered pharmacoki-
netics, including ARC, in critically ill patients on bacterial killing and emergence of
resistance by meropenem using a HFIM. When subjected to widely varying renal
functions and thus meropenem clearances, substantial differences in bacterial killing
and the emergence of less-susceptible populations occurred between commonly used
dosing regimens against a susceptible P. aeruginosa isolate with a low meropenem MIC.
Although all regimens in the presence of renal impairment achieved substantial
bacterial killing (i.e., with no viable bacteria detected on 1 occasion) and the sup-
pression of regrowth, minimal killing with rapid regrowth and substantial increases in
less-susceptible populations occurred with all regimens in the presence of ARC. Wor-
ryingly, regrowth and large increases in less-susceptible populations similarly occurred
with 0.5- and 1-g regimens with normal renal function, with only the 2-g regimen
resulting in substantial and prolonged bacterial killing and resistance suppression.
Individualized dosing regimens accounting for altered pharmacokinetics and aiming for
higher than standard antibiotic exposures are necessary to maximize bacterial killing
(100% fT5MIC) and suppress resistance emergence (fCmin/MIC  2). Such exposures
will be difﬁcult to achieve using standard short-term infusions in the presence of
ARC. Optimized dosing regimens, including extended infusions and/or combina-
tions, supported by MBM and Monte Carlo simulations, should be evaluated in the
context of ARC.
MATERIALS AND METHODS
Antibiotic, media, bacterial isolate, and susceptibility testing. Meropenem (lot MAUS1025;
Fresenius Kabi, New South Wales, Australia) stock solutions were prepared as described previously (14).
Viable counting was performed on cation-adjusted Mueller-Hinton agar (CAMHA; 25 mg/liter Ca2 and
12.5 mg/liter Mg2; University of Melbourne, Melbourne, Australia). Drug-containing agar plates were
prepared by adding meropenem stock solution to CAMHA (lot 5030699; BD, Sparks, MD). HFIM studies
were performed using cation-adjusted Mueller-Hinton broth (CAMHB; lot 3322206; BD) containing 20 to
25 mg/liter Ca2 and 10 to 12.5 mg/liter Mg2. Clinical isolate P. aeruginosa 1280 (meropenem MIC, 0.25
mg/liter; Royal Brisbane and Women’s Hospital, Australia) was obtained from a critically ill patient with
a soft tissue infection. MICs prior to and following drug exposure were determined using the Clinical and
Laboratory Standards Institute agar dilution method (56). Susceptibility and resistance were deﬁned as
MICs of 2 and 8 mg/liter, respectively (57).
HFIM. A hollow-ﬁber in vitro infection model (HFIM; 36°C) was used to evaluate changes in bacterial
burden and the suppression of resistance with four commonly used meropenem dosing regimens.
Cellulosic cartridges (batch B720170715b; FiberCell Systems, Inc., Frederick, MD) were used. An initial
inoculum of107.5 CFU/ml was prepared as described previously (14). Experiments were conducted over
10 days with periodic sampling (1.0 to 1.5 ml) for viable counting (Table 4). Samples were twice
centrifuged (4,000 g, 5 min), resuspended in saline to reduce antibiotic carryover, and manually plated
on CAMHA containing no drug (100 l plated; limit of counting, 1.0 log10 CFU/ml) and meropenem at
5 and 10 MIC (see “Mutation frequency and emergence of resistance studies” below).
Experimental design and simulated meropenem regimens. The free (non-protein-bound) plasma
concentration-time proﬁles based on a population pharmacokinetic model for meropenem in critically ill
patients (protein binding 2%) (20) and a fraction excreted unchanged in urine of 79% of a meropenem
dose in subjects with normal renal function (58) were ﬁrst simulated using Berkeley Madonna (v8.3.18).
Proﬁles were simulated for patients with different drug clearances due to altered renal function, namely,
patients with ARC (creatinine clearance [CLCR],285 ml/min; meropenem clearance, 34.0 liters/h; half-life
[t1/2], 0.6 h), normal renal clearance (CLCR, 120 ml/min; meropenem clearance, 16.3 liters/h; t1/2, 1.1 h), and
renal impairment (CLCR,10 ml/min; meropenem clearance, 4.1 liters/h; t1/2, 4 h) (Table 4). For each level
of renal function, the in silico simulations evaluated dosing regimens of 2, 1, and 0.5 g of meropenem
administered via a 30-min i.v. infusion given every 8 h (Table 4) (59). A further 1-g regimen, administered
via a 30-min i.v. infusion every 12 h, as used in patients with renal impairment, was also evaluated via
simulation. The ﬁnal simulated meropenem concentration-time proﬁles were then generated in the
HFIM. No loading dose was administered. Untreated growth controls were included.
Mutation frequency and emergence of resistance studies.Mutation frequencies were determined
at baseline (0 h) and at 23, 47, 71, 95, 119, 143, 167, 191, 215, and 239 h to quantify less-susceptible
subpopulations. A 200-l sample of appropriately diluted log-phase growth suspension was manually
plated onto CAMHA containing no antibiotic and meropenem at 5 and 10 MIC (i.e., 1.25 and 2.5
mg/liter meropenem). Given the potential for a low number of less-susceptible bacteria in samples from
untreated controls and some treatment regimens, 200 l was used to increase sensitivity (limit of
Bergen et al. Antimicrobial Agents and Chemotherapy
May 2017 Volume 61 Issue 5 e02642-16 aac.asm.org 10
 o
n
 M
ay 10, 2018 by University of Queensland Library
http://aac.asm
.org/
D
ow
nloaded from
 
counting, 0.7 log10 CFU/ml). For determination of total and less-susceptible counts at baseline, log-phase
growth suspension was used, and enumeration was performed manually after 24 h of incubation at 36°C.
The log10 (mutation frequency) (log10MF) was determined as follows: log10MF  log10(CFU/ml on
antibiotic-containing agar)  log10(CFU/ml on antibiotic-free agar).
Although some viable counts were too low to quantify colonies on antibiotic-containing agar, these
samples provided information on the upper limit of the log10MF. To conﬁrm changes in MIC from
baseline, MICs were determined at 47 and 191 h using a subset of at least three colonies from
antibiotic-free and antibiotic-containing plates.
Measurement of meropenem concentrations. Duplicate (1-ml) samples were collected periodically
(Table 4) in cryovials and stored at 80°C. Concentrations were measured at ambient temperature using
a validated high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS)
method. The HPLC-MS/MS system comprised two Shimadzu Nexera2 LC-30AD liquid chromatographs, a
SIL-30ACMP autosampler, and an 8030 triple-quadrupole detector (Shimadzu, Tokyo, Japan). To a
2.5-l sample, 10 l of 0.5 g/ml meropenem-d6 (internal standard) and 30 l of acetonitrile were added
before centrifugation (5 min, 13,000  g). A 30-l volume of supernatant was removed to an autosam-
pler vial, and 0.5 l was injected onto a SeQuant ZIC-HILIC 5.0-m column (2.1 by 50 mm; Merck,
Darmstadt, Germany). The mobile phase consisted of 80% acetonitrile, 20% water, and 0.1% formic acid
delivered isocratically at 0.3 ml/min. Meropenem was monitored by positive-mode electrospray at
multiple reaction monitoring of 383.50¡68.15, 383.50¡114.15, and 383.50¡141.10. Meropenem-d6
was monitored in positive mode at 390.10¡147.10 and 390.10¡73.90. The run time was 3.2 min, and
the assay range was 0.2 to 100 mg/liter; samples were diluted when the expected concentrations
exceeded the upper limit of quantiﬁcation. Unknown samples were assayed in batches alongside
calibration and quality control samples, and the results were subjected to batch acceptance criteria. The
assay method was validated for linearity, lower limit of quantiﬁcation, precision, and accuracy according
to both U.S. Food and Drug Administration and European Medicines Evaluation Agency criteria (60, 61).
The precision was within 4.9% and the accuracy was 8.1% at the concentrations tested (0.60, 4.0, and 80
mg/liter).
Pharmacodynamic modeling. Modeling was conducted using importance sampling (pmethod 4)
in parallelized S-ADAPT with SADAPT-TRAN (62–64). All pharmacokinetic and pharmacodynamic obser-
vations were ﬁtted simultaneously. Models were evaluated based on the S-ADAPT objective function
(1log-likelihood), standard diagnostic plots, visual predictive checks, and plausibility of the parameter
estimates (14, 54, 65). Models with one, two, and three bacterial subpopulations and which described the
effect of meropenem via direct bacterial killing, the inhibition of successful bacterial replication, or both
were evaluated (54, 66, 67).
The ﬁnal model incorporated three subpopulations that were susceptible (CFUS), intermediate (CFUI)
or resistant (CFUR) to meropenem. The size of the total inoculum (logCFU0) and the log10 mutation
frequencies for the intermediate (logMFI) and resistant (logMFR) subpopulations were estimated param-
eters. Thus, the estimated subpopulations did not directly reﬂect bacterial counts on meropenem-
containing agar plates at 5 and 10MIC. Each subpopulation contained bacteria in two states: those
preparing for replication (CFU1) and those immediately before replication (CFU2) (53, 67). The total
concentration of viable bacteria (CFUALL) was calculated as follows:
CFUALL CFUS1 CFUS2 CFUI1 CFUI2 CFUR1 CFUR2
The initial condition of the CFUS population was calculated as the difference between the total inoculum
(CFU0, i.e., the value of CFUALL at time 0 h) and the initial conditions of the CFUI and CFUR populations.
All bacteria were initialized in state 1, and the initial conditions for CFUS2, CFUI2, and CFUR2 were 0.
The concentration of meropenem-susceptible bacteria in state 1 (CFUS1) was determined as follows:
dCFUS1
dt
 REP · 1 lnhRep,s · k21 · CFUS2 k12,s · CFUS1
where k21 is the replication rate constant, k12,S is the growth rate constant, and REP is the replication
factor:
REP 2 · 1 CFUALL
CFUmax  CFUALL

At a low CFUALL, REP approached 2, representing a 100% probability of successful replication. As CFUALL
approached the maximum population size (CFUmax), REP approached 1, i.e., a 50% probability of
successful replication with the total viable count remaining constant.
The effect of meropenem is best described as the inhibition of successful replication (InhRep,S):
lnhRep,S
Imax Rep,S · CHill,S
IC50Rep,S
Hill,S CHill,S
where C is the meropenem concentration in the growth medium, Imax Rep,S is the maximum inhibition of
successful replication, IC50 Rep,S is the concentration causing 50% of the maximum inhibition effect, and
Hill,S is the Hill coefﬁcient. An InhRep,S value of 0.50 resulted in net stasis, whereas an InhRep,S value of
0.50 led to bacterial killing due to the elimination of bacteria that replicate unsuccessfully.
The concentration of meropenem-susceptible bacteria in state 2 (CFUS2) was determined as follows:
dCFUS2
dt
k21 · CFUS2 k12,S · CFUS1
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The bacterial concentrations of the intermediate and the resistant subpopulations were described in a
similar manner. The biological variability between the viable count curves was assumed to be log-
normally distributed, except for parameters constrained between 0 and 1 that were logistically trans-
formed. Between-curve variability was set to 15% coefﬁcient of variation during the end of the estimation
(65). An additive residual error model was used to ﬁt the viable counts. For observations 100 CFU/ml
the number of colonies/plate was directly ﬁtted via a previously developed residual error model (53).
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